Largest pharmaceuticals by total debt
Borrowings at the end of the latest fiscal year: long-term debt including the part due within a year, plus short-term borrowings. Leases are left out unless the company reports them in one figure with its debt.
AbbVie leads the 35 pharmaceuticals ranked by total debt, at PLN 271.7B, ahead of Pfizer (PLN 260.8B) and Merck & Co (PLN 198.5B). Figures as of 18 Nov 2026, 16:15 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 35
- First
- AbbViePLN 271.7B
- Median
- PLN 21.2B
- Combined market value
- PLN 20.45T
- Countries
- 10
- Not ranked
- 26no total debt on file
Market values as of .
All countries▾
All sectors▾
Pharmaceuticals▾
| # | Company | Total debt ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | AbbVieABBV · Health Care | PLN 271.7B | PLN 2.05T | PLN 1,160.19 | 1.57% down | 26% up | ||
| 2 | PfizerPFE · Health Care | PLN 260.8B | PLN 645.9B | PLN 113.32 | 1.12% down | 14% up | ||
| 3 | Merck & CoMRK · Health Care | PLN 198.5B | PLN 1.38T | PLN 561.50 | 2.71% down | 51% up | ||
| 4 | Johnson & JohnsonJNJ · Health Care | PLN 193B | PLN 2.67T | PLN 1,107.54 | 1.28% down | 38% up | ||
| 5 | Bristol-Myers SquibbBMY · Health Care | PLN 181.6B | PLN 493.4B | PLN 241.37 | 2.27% down | 34% up | ||
| 6 | Eli LillyLLY · Health Care | PLN 171.1B | PLN 4.98T | PLN 5,587.70 | 1.94% down | 35% up | ||
| 7 | Takeda PharmaceuticalTAK · Health Care | PLN 123.1B | PLN 274.7B | PLN 85.98 | 1.29% down | 54% up | ||
| 8 | AstraZenecaAZN · Health Care | PLN 119.2B | PLN 1.12T | PLN 719.34 | 1.96% down | 2% up | ||
| 9 | NovartisNVS · Health Care | PLN 115.6B | PLN 1.19T | PLN 628.46 | 1.89% down | 25% up | ||
| 10 | SanofiSNY · Health Care | PLN 83.5B | PLN 457.2B | PLN 190.39 | 0.49% down | 4% down | ||
| 11 | Novo NordiskNVO · Health Care | PLN 78.2B | PLN 703.8B | PLN 159.68 | 2.54% down | 17% down | ||
| 12 | GSKGSK · Health Care | PLN 77.2B | PLN 393.4B | PLN 196.28 | 0.97% down | 6% up | ||
| 13 | ViatrisVTRS · Health Care | PLN 58B | PLN 95.3B | PLN 83.15 | 1.00% up | 96% up | ||
| 14 | Abbott LaboratoriesABT · Health Care | PLN 52B | PLN 726.3B | PLN 419.34 | 0.52% down | 17% down | ||
| 15 | ZoetisZTS · Health Care | PLN 36.4B | PLN 137B | PLN 337.12 | 0.32% up | 29% down | ||
| 16 | Royalty PharmaRPRX · Health Care | PLN 36B | PLN 158.4B | PLN 275.51 | 0.35% down | 78% up | ||
| 17 | Jazz PharmaceuticalsJAZZ · Health Care | PLN 21.6B | PLN 62.9B | PLN 980.31 | 1.17% up | 37% up | ||
| 18 | GenmabGMAB · Health Care | PLN 21.2B | PLN 127.4B | PLN 206.59 | 1.23% down | 70% up | ||
| 19 | Elanco Animal HealthELAN · Health Care | PLN 16.2B | PLN 53B | PLN 106.13 | 1.99% up | 20% up | ||
| 20 | Amneal PharmaceuticalsAMRX · Health Care | PLN 10.4B | PLN 30.2B | PLN 86.67 | 1.94% up | 83% up | ||
| 21 | BridgeBio PharmaBBIO · Health Care | PLN 8.1B | PLN 60.8B | PLN 312.34 | 1.03% up | 17% up | ||
| 22 | Regeneron PharmaceuticalsREGN · Health Care | PLN 8B | PLN 397.4B | PLN 3,841.70 | 0.36% down | 36% up | ||
| 23 | Ionis PharmaceuticalsIONS · Health Care | PLN 7.3B | PLN 18.3B | PLN 110.00 | 1.35% up | 64% down | ||
| 24 | BeOne MedicinesONC · Health Care | PLN 4.1B | PLN 185.7B | PLN 1,625.46 | 2.29% down | 17% up | ||
| 25 | Ascendis PharmaASND · Health Care | PLN 3.2B | PLN 71.2B | PLN 1,085.87 | 0.53% down | 28% up | ||
| 26 | InsmedINSM · Health Care | PLN 2.2B | PLN 106B | PLN 483.08 | 1.52% down | 40% down | ||
| 27 | Madrigal PharmaceuticalsMDGL · Health Care | PLN 1.4B | PLN 38.3B | PLN 1,649.61 | 2.89% down | 24% down | ||
| 28 | Legend BiotechLEGN · Health Care | PLN 1.3B | PLN 12.7B | PLN 65.37 | 0.81% up | 42% down | ||
| 29 | CytokineticsCYTK · Health Care | PLN 1.2B | PLN 28.7B | PLN 205.94 | 0.95% down | 20% down | ||
| 30 | TG TherapeuticsTGTX · Health Care | PLN 988.8M | PLN 39.3B | PLN 259.83 | 2.93% up | 107% up | ||
| 31 | Cogent BiosciencesCOGT · Health Care | PLN 897.3M | PLN 19.9B | PLN 114.34 | 1.99% up | 20% down | ||
| 32 | Dr. Reddy's LaboratoriesRDY · Health Care | PLN 779.8M | PLN 50.2B | PLN 60.27 | 1.23% up | 5% up | ||
| 33 | Axsome TherapeuticsAXSM · Health Care | PLN 755.8M | PLN 28.3B | PLN 537.20 | 1.84% down | 7% down | ||
| 34 | Rhythm PharmaceuticalsRYTM · Health Care | PLN 435.5M | PLN 32.6B | PLN 469.78 | 0.08% up | 13% up | ||
| 35 | Definium TherapeuticsDFTX · Health Care | PLN 163.4M | PLN 15.7B | PLN 114.67 | 3.05% down | 169% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Total debt is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Total debt is assembled from each company's debt lines and is the least complete of these figures: some companies tag part of their borrowings in ways it misses. Sums are converted from US dollars at today's exchange rate (1 USD = 4.0255 PLN). 26 companies have no total debt on file and are not ranked here.
Questions and answers
Which pharmaceuticals rank first by total debt?
AbbVie (PLN 271.7B), Pfizer (PLN 260.8B) and Merck & Co (PLN 198.5B) are the top three of the 35 pharmaceuticals ranked by total debt as of 18 Nov 2026, 16:15 UTC.
How many pharmaceuticals are in this ranking?
35 are ranked by total debt. 26 more have no total debt on file and are left out rather than ranked at zero.
What are these pharmaceuticals worth together?
The 35 pharmaceuticals ranked by total debt have a combined market value of PLN 20.45T as of 18 Nov 2026, 16:15 UTC.
What does ranking by total debt measure?
Borrowings at the end of the latest fiscal year: long-term debt including the part due within a year, plus short-term borrowings. Leases are left out unless the company reports them in one figure with its debt.
Learn how this ranking works
All markets guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Largest pharmaceuticals by total debt”, data as of 18 November 2026. https://funkfolio.com/companies/category/pharmaceuticals?by=total-debt
Underlying data: Yahoo Finance; SEC EDGAR.